T&R Biofab

At a glance

T&R Biofab filed 89 disclosures in the last 12 months, including 38 insider, 15 5% holder and 4 earnings. The most recent key filing was on Oct 19.

Revenue for 2025 was ₩27B, up 453.3% on 2024. It made an operating loss of ₩9.1B. Debt was 256% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩18.3B and operating loss of ₩1.9B.

The 2025 annual report lists 82 employees with an average tenure of 2.8 years and average pay of ₩51.4M, #1388 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩101M each on average. It paid no cash dividend for 2025. 윤원수 and related parties held 15.08% at year end.

From the 2025 annual report

Staff: 82 (52 men, 30 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.2B. Directors and auditors: 7, paid ₩708M in total.

No cash dividend was paid for 2025.

Largest shareholder

윤원수 holds 10.70%; with 3 related parties the group holds 15.08% of common shares at year end (from 26.05% at the start of the year).

Auditor: 태성회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary